Physician
Hematology
Dr. Peter D. Boasberg, MD
|
|
Give Review
Peter Boasberg is an expert in the field of Hematology. He attended University of California Irvine School of Medicine. University of California Irvine School of Medicine is ranked 45/62 in Research/PrimaryCare. He over the years received 2 awards: "Top MD" and "Super Doctor". Dr. Peter D. Boasberg has written publications. He has 30 publications published with PubMed. The lastest paper is: 'Immunocompetence and spontaneous regression of metastatic renal cell carcinoma.' Peter Boasberg accepts Medicare.
Publications
- Phase II study of nab-paclitaxel and bevacizumab as first-line therapy for patients with unresectable stage III and IV Melanoma.
- Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced Melanoma.
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced Melanoma: a randomised dose-comparison cohort of a phase 1 trial.
- BRAF-Targeted Therapy to Treat Superior Vena Cava Syndrome in a Patient With Metastatic Cancer.
- Safety and tumor responses with lambrolizumab (anti-PD-1) in Melanoma.
- Systemic treatment of metastatic melanoma: New approaches.
- Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast Cancer, and colon Cancer.
- Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic Melanoma.
- Circulating DNA microsatellites: molecular determinants of response to biochemotherapy in patients with metastatic Melanoma.
- Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic Cancer vaccine.
- Maintenance biotherapy for metastatic Melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to ind...
- Biochemotherapy for metastatic melanoma with limited central Nervous system involvement.
- Integrative tumor board: Advanced breast Cancer.
- Screening-detected breast Cancer in a man with BRCA2 mutation: case report.
- Impact of gene polymorphisms on clinical outcome for stage IV Melanoma patients treated with biochemotherapy: an exploratory study.
- Management of metastatic Melanoma 2005.
- Colon carcinoma and the Cancer family syndrome.
- Breast Cancer: lack of prognostic value of adrenal pathology at adrenalectomy.
- Case reports and studies of paraneoplastic hypotension: abnormal low pressure baroreceptor responses.
- Immunocompetence and spontaneous regression of metastatic renal cell carcinoma.
- Estrogen-induced hypercalcemia.
- Lymphocyte transfusion therapy for Cancer patients.
- Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melan...
- High-dose tamoxifen added to concurrent biochemotherapy with decrescendo interleukin-2 in patients with metastatic Melanoma.
- Paraneoplastic chorea associated with CRMP-5 neuronal antibody and Lung carcinoma.
- Prognostic factors in metastatic Melanoma patients treated with biochemotherapy and maintenance immunotherapy.
- Phase II multicenter trial of maintenance biotherapy after inDuction concurrent Biochemotherapy for patients with metastatic melanoma.
- Serial monitoring of circulating tumor cells predicts outcome of inDuction biochemotherapy plus maintenance biotherapy for metastatic melanoma.
- Ipilimumab: unleashing the power of the immune System through CTLA-4 blockade.
Schools
Univ Of Ca
Good Samaritan Hospital
Wadsworth Va Hospital
Los Angeles Cousc Can Center
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Antiphospholipid Syndrome (APS)
- View All
Doctors Specialties
- Hematology
- Oncology
Accepted Insurances
Awards
- Top MD
- Super Doctor
Education
-
University of Southern California - LAC+USC Medical Center -
VA Greater Los Angeles Healthcare System -
University of California Irvine School of Medicine
Hospital
-
Ronald Reagan UCLA Medical Center
Drug Facts
| NPI NUMBER | 1417982331 | |
| NPPES Provider LastName | BOASBERG | |
| NPPES Provider FirstName | PETER | |
| NPPES Provider ZIPCode | 904042102 | |
| NPPES Provider State | CA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 914.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 41.0 | |
| Percent Opioid Claims | 4.49 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1417982331 |
| Last Name Of The Provider | BOASBERG |
| First Name Of The Provider | PETER |
| View All |
Similar Doctors
|
|
Dr. Daniel J. Lieber, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carol Y. Nishikubo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rena D. Callahan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sara A. Hurvitz, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Andrew E. Hendifar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Silvana Martino, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jonathan W. Goldman, MD |
|
|
Dr. Leonard S. Goldberg, MD |
|
|
Dr. Jonathan W. Simons, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Kathryn A. Henick, MD |
|
|
Dr. Saeed W. Sadeghi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sven Devos, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John M. Timmerman, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|